Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

United Therapeutics

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of United Therapeutics' 2013 cardiovasular sales performance.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

have a treatment option in the form of Wellstat Therapeutics' Xuriden (uridine triacetate). ... USA. dinutuximab. Unituxin. neuroblastoma. anti-GD2 antibody. United Therapeutics. USA. elotuzumab. Empliciti.

FDA approvals hit 19-year high

FDA approvals hit 19-year high Orkambi (ivacaftor plus lumacaftor) and United Therapeutics' paediatric bran cancer therapy Unituxin (dinutuximab).

Actelion claims first approval for PAH therapy Uptravi

Actelion claims first approval for PAH therapy Uptravi Uptravi will compete in the US marketplace with another oral prostacyclin agonist - United Therapeutics' Orenitram (treprostinil) - and Actelion is banking that the data behind its new drug will allow it to

GSK earns expanded approval for Volibris in Europe

GSK earns expanded approval for Volibris in Europe s Adempas (riociguat) and United Therapeutics' Orenitram (trepostinil).

Gilead receives FDA approval for PAH combo

Gilead receives FDA approval for PAH combo Additionally there will be competition from Bayer's Adempas (riociguat), which was cleared by the FDA in 2013, and United Therapeutics' Remodulin (treprostinil).

1 2 3 4 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics